Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Burnett Patrick

Vairavan Latha

Watanabe Todd

Matsuda Masaru

Welgus Howard G.

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Arcutis Biotherapeutics granted an aggregate of 44,000 restricted stock units to six newly hired employees as a material inducement for employment. The RSUs vest over four years with 25% vesting annually, subject to continuous employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

Arcutis Biotherapeutics Inc (ARQT) Stock Price, Analysis & Trade Signals